Filing Details

Accession Number:
0001209191-19-030503
Form Type:
4
Zero Holdings:
No
Publication Time:
2019-05-16 17:21:16
Reporting Period:
2019-05-14
Accepted Time:
2019-05-16 17:21:16
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1505512 Regulus Therapeutics Inc. RGLS Pharmaceutical Preparations (2834) 264738379
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1762611 Ray Christopher Aker C/O Regulus Therapeutics Inc.
10628 Science Center Dr., #100
San Diego CA 92121
Sr. Vp & General Counsel No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2019-05-14 38,512 $0.00 66,259 No 4 A Direct
Common Stock Disposition 2019-05-15 6,950 $1.41 59,309 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 A Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (Right to Buy) Acquisiton 2019-05-14 7,500 $0.00 7,500 $0.95
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
7,500 2019-05-14 2029-02-04 No 4 A Direct
Footnotes
  1. On November 11, 2018, the reporting person was granted Restricted Stock Units in the Company's tender offer. The RSUs vest only upon the achievement of a performance-based milestone. The performance criteria were met, resulting in vesting of the RSUs. Upon achievement of the milestone, 50% of the RSU subject to the milestone immediately vest, with the remaining RSUs vesting quarterly in the 24 months following the vesting commencement date.
  2. The sales reported on this Form 4 represent shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units (RSUs) received by the Reporting Person on 5/14/2019. These sales are made pursuant to an existing 10b5-1 plan under which the Reporting Person has irrevocably elected to satisfy the tax obligations through this sale and do not represent discretionary trades by the Reporting Person.
  3. On February 5, 2019, the reporting person was granted an option to purchase the number of shares of common stock set forth in Box 5. The option vests only upon the achievement of a performance-based milestone. The performance criteria were met, resulting in vesting of the option. Upon achievement of the milestone, 50% of the options subject to the milestone immediately vest, with the remaining options vesting in 24 equal monthly installments following the vesting commencement date.